MENLO PARK, CA: Revenue Increases 177 Percent From the Comparable Period in Prior Year and 24 Percent From Prior Quarter on Continued Uptake of Korlym(R) for the Treatment of Cushing's Syndrome; GAAP Net Loss De ...
SAN DIEGO, CA: Once All of the FDA Comments Are Addressed, the Company Aims to Initiate Gene Silencing Immunotherapy for Metastatic Breast Cancer Patients
...
CEDAR KNOLLS, NJ: Daily Use of Fortetropin Does Not Adversely Affect Cholesterol, HDL or Triglycerides; Company Announces New Data From The University of Tampa Clinical Data Conducted in 1H 2014
...
SOUTH SAN FRANCISCO, CA: 240 mg Achieved a Median Maximal Viral Load Decline of 4.9 Log10 IU/mL Following Three Daily Doses in Genotype 1a Patients
...
Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.